EDRN Genitourinary (GU) Prostate Collaborative Group Meeting Agenda
EDRN Genitourinary (GU) Prostate Collaborative Group Meeting
Wednesday, September 17, 2025, 9:00 a.m. – 1:00 p.m.
Location: Eastlake E1-101
Chair: Jeffrey J Tosoian, MD, Vanderbilt University Medical Center
Co-Chair: O. John Semmes, PhD, Eastern Virginia Medical School
NCI Program Directors: Indu Kohaar, PhD (Primary), Guillermo Marquez, PhD
DMCC Staff: Kristin Rodgers, Yingye Zheng, PhD, Fred Hutchinson Cancer Center
Wednesday, September 17, 2025
Start End Title / Topic Presenter / Institution Number
9:00am 9:05am Welcome Indu Kohaar, PhD, National Cancer Institute N/A
9:05am 9:30am Invited Talk
  • Elai Davicioni, PhD, Senior Vice President & Medical Director, Urology, Veracyte
 01
Progress Update by Biomarker Characterization Centers
Brief presentation by BDLs and BRLs of BCCs on the approaches they are currently using, completed aims, and current aims (15 min, 5 min Q&A)
9:30am 9:50am Q&A (5m) Michigan-VUMC Biomarker Characterization Center
  • Arul Chinnaiyan, MD, PhD, University of Michigan
  • Jeffrey Tosoian, MD, Vanderbilt University Medical Center
 02
9:50am 10:10am Q&A (5m) Virginia-UCLA-Toronto Biomarker Characterization Center
  • John Semmes, PhD, Eastern Virginia Medical School
  • Paul Boutros, PhD, The University of California, Los Angeles
  • Thomas Kislinger, PhD, Princess Margaret Cancer Centre, University Health Network, University of Toronto
 03
10:10am 10:30am Q&A (5m) Johns Hopkins Biomarker Characterization Center
  • Hui Zhang, PhD, Johns Hopkins University School of Medicine
  • Zheng Zhang, PhD, The Johns Hopkins University
 04
10:30am 10:50am Q&A (5m) Emory-UAB-UTSW Prostate Cancer Biomarker and Imaging Validation Alliance
  • Martin G. Sanda, MD, Emory University
 05
10:50am 11:10am Q&A (5m) NCI EDRN MRI Biomarker Study and Reference Set (PMRI)
  • John T. Wei, MD, MS, University of Michigan
 06
11:10am 11:20am Break
11:20am 11:50pm Q&A (10m) Invited Talk
  • Li Ding, PhD, Washington University
 07
11:50am 12:50pm Open discussion on new perspectives and focus areas that can be coordinated across the group including BCCs and CVCs, and across BRLs (60 min)
  1. What specific approaches and biomarkers appear most promising? Which approaches and biomarkers are ready to be moved to validation?
  2. Discuss cross-center collaborations that will facilitate validation of these approaches and biomarkers -considering available and developing data from CVCs, reference sets.
  3. Future directions on how we can collaborate with early detection research consortia including Cancer Screening Research Network
  4. Knowledge gaps and opportunities in prostate early detection
Moderators: Chairs of GU Committee		 N/A
12:50pm 1:00pm Closing Remarks N/A
1:00pm 1:00pm ADJOURN


If you have any questions regarding meeting registration, please contact EDRN DMCC at edrndmcc@fredhutch.org.

 
 
The meeting registration form created by EDRN DMCC at Fred Hutchinson Cancer Center ©